30 closest matches · ranked by relevance
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Neovascular Age-related Macular Degeneration · Wet Age-related Macular Degeneration
Primary: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) — 6; 6; 6; 12 Participants
Glioblastoma
Primary: Number of Patients Alive and Progression Free After 6 Months — 1 Participants
Carcinoma, Renal Cell
Primary: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs) — 215; 31; 32; 16 Participants
Gastrointestinal Cancer
Primary: Everolimus Maximum Tolerated Dose (MTD) [Phase I] — 10 mg daily for 4 weeks of a 4 week cycle
Lung Cancer · Lung Metastases
Primary: Clinically Significant Events (CSE) — 0.449 Proportion of subjects — p=<.0001
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
Advanced or Metastatic Gastric Cancer
Primary: Progression Free Survival(PFS) — 2.6; 1.8 month
Epidermolysis Bullosa · Pruritus
Primary: Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period — -2; -1 score/week comparative change
Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 9.3; 10.1 Months
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Carcinoid Tumor
Primary: Progression Free Survival — 11.8 months
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 1 participants
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Neuroendocrine Carcinoma
Primary: Objective Response Rate (ORR) — 16; 18; 16 percentage of participants
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…
Adult Alveolar Soft Part Sarcoma · Adult Angiosarcoma · Adult Desmoplastic Small Round Cell Tumor
Primary: Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level…
Chronic Migraine
Primary: Change in Gray Matter Thickness in the Somatosensory Cortex — -0.043; 0 mm
Progressive Supranuclear Palsy
Primary: Change From the Baseline in the Total Score of PSP-rating Scale — 4.10; 2.14; 6.46 scores on a scale
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Glioblastoma Multiforme
Primary: Percentage of Subjects With Progression-free Survival — 7.5; 15.0 percentage of subjects
Astrocytoma, Grade III · Glioblastoma
Primary: Maximum Tolerated Dose (MTD) — 150; 150 mg
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024
Esophagogastric Adenocarcinoma
Primary: 6-month Progression-free Survival (PFS) — 1.9 months
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale